Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Auxora
2. Cm 4620
3. Cm-128
4. Cm-4620
5. Cm128
6. Cm4620
7. N-(5-(6-chloro-2,2-difluorobenzo(d)(1,3)dioxol-5-yl)pyrazin-2-yl)-2-fluoro-6-methylbenzamide
8. Zegocractin
1. Cm-4620
2. 1713240-67-5
3. Zegocractin
4. Cm4620
5. Zegocractin [inn]
6. Chembl4753998
7. 564aw1rr37
8. N-[5-(6-chloro-2,2-difluoro-1,3-benzodioxol-5-yl)pyrazin-2-yl]-2-fluoro-6-methylbenzamide
9. Benzamide, N-(5-(6-chloro-2,2-difluoro-1,3-benzodioxol-5-yl)-2-pyrazinyl)-2-fluoro-6-methyl-
10. N-(5-(6-chloro-2,2-difluorobenzo(d)(1,3)dioxol-5-yl)pyrazin-2-yl)-2-fluoro-6-methylbenzamide
11. Cm 4620
12. Unii-564aw1rr37
13. Schembl18038390
14. Gtpl10087
15. Cm-4620 [who-dd]
16. Cm 4620 Pound>>cm4620
17. Dtxsid901337267
18. Bcp29536
19. Ex-a1898
20. Bdbm50575336
21. S6834
22. Compound I [wo2016138472a1]
23. Sb18686
24. Ac-35758
25. Bs-15636
26. Hy-101942
27. Cs-0022201
28. C73294
29. N-[5-(6-chloro-2,2-difluoro-1,3-benzodioxol-5-yl)-2-pyrazinyl]-2-fluoro-6-methylbenzamide
Molecular Weight | 421.8 g/mol |
---|---|
Molecular Formula | C19H11ClF3N3O3 |
XLogP3 | 4.3 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 8 |
Rotatable Bond Count | 3 |
Exact Mass | 421.0441034 g/mol |
Monoisotopic Mass | 421.0441034 g/mol |
Topological Polar Surface Area | 73.3 Ų |
Heavy Atom Count | 29 |
Formal Charge | 0 |
Complexity | 617 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
ABOUT THIS PAGE
A Zegocractin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Zegocractin, including repackagers and relabelers. The FDA regulates Zegocractin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Zegocractin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Zegocractin supplier is an individual or a company that provides Zegocractin active pharmaceutical ingredient (API) or Zegocractin finished formulations upon request. The Zegocractin suppliers may include Zegocractin API manufacturers, exporters, distributors and traders.
Zegocractin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Zegocractin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Zegocractin GMP manufacturer or Zegocractin GMP API supplier for your needs.
A Zegocractin CoA (Certificate of Analysis) is a formal document that attests to Zegocractin's compliance with Zegocractin specifications and serves as a tool for batch-level quality control.
Zegocractin CoA mostly includes findings from lab analyses of a specific batch. For each Zegocractin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Zegocractin may be tested according to a variety of international standards, such as European Pharmacopoeia (Zegocractin EP), Zegocractin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Zegocractin USP).
LOOKING FOR A SUPPLIER?